Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial

In adults hospitalized with acute severe ulcerative colitis who fail to respond to intravenous steroids, does treatment with a combination of infliximab and tofacitinib, compared with infliximab alone or tofacitinib alone, result in higher rates of early clinical remission and mucosal healing, and fewer treatment-related complications over a 10 week period

NCT Number	NCT07297069
Lead Sponsor	Asian Institute of Gastroenterology, India
Conditions	Acute Severe Ulcerative Colitis
Enrollment	60 participants
Start Date	2026-01-01
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-24